Search

everythinglearnresearchcommunity

for

Search:↓

Topical immunotherapy can treat alopecia areata, but its effectiveness varies and the exact mechanism is unclear.

Autoimmune and metabolic issues are linked, and treating one may worsen another.

Mixing platelet-rich plasma with triamcinolone acetonide can potentially improve hair regrowth in alopecia areata patients.

Asian patients with Frontal Fibrosing Alopecia often lose eyebrow hair and respond well to combined antiandrogen or antimalarial and topical treatments.

The document concludes that accurate diagnosis of alopecia in children relies on thorough examination and history, and while treatments exist, none can alter the course of alopecia areata, which can significantly affect a child's psychological well-being.

People with moderate hair loss from Alopecia Areata feel more impacted than those with no or almost complete hair loss, and are more likely to seek treatment.

LED therapy can safely and effectively regrow eyebrows in people with frontal fibrosing alopecia.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

A woman's hair loss led to discovering she had lupus.

Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Alopecia Areata affects people of all ages worldwide, is likely caused by genetic and environmental factors, and can lead to stress and depression, highlighting the need for treatments that address both physical and mental health.

Patients were highly satisfied with shared medical appointments for hair loss treatment.

Ayurvedic treatment successfully regrew hair in a 7-year-old girl with alopecia areata.

Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

Dermoscopy is a useful tool for diagnosing and managing alopecia areata.

Alopecia areata is an incurable autoimmune condition causing hair loss, with research aiming for better treatments.

Alopecia Areata (AA) causes significant emotional distress, including feelings of embarrassment, depression, and anxiety, and impacts social interactions and daily activities.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Some treatments like pentoxifylline with topical corticosteroids might work for alopecia areata, but more research is needed to find the best one.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Yellow dots are common in severe alopecia areata.

Nivolumab can cause hair loss as a rare side effect.

Mesalazine may help treat extensive alopecia areata effectively.

JAK inhibitors offer new hope for treating severe alopecia areata.

Mogamulizumab can cause hair loss and skin rashes.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Both concentrations of triamcinolone acetonide are effective for hair regrowth in patchy alopecia areata, but 5 mg/mL is recommended to reduce side effects.

Higher levels of CCL7 are linked to more severe hair loss in alopecia areata patients.